EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY 4.0

Treatment outcomes of prolonged induction or re-escalation dosing of upadacitinib in patients with inflammatory bowel disease

Ellen Axenfeld, Vasantham Chaudhary iD, Joseph W Clinton, Michael Frohlinger, Lauren George, Raymond K Cross, Jordan E Axelrad

Crohn’s & Colitis 360 · 22.04.2026 · 8 (2)

DOI: 10.1093/crocol/otag021 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Crohn’s & Colitis 360, online erschienen am 29.04.2026. Verfasst von Ellen Axenfeld und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY, United States. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Proposed treatment algorithms favor the use of upadacitinib in medically refractory Crohn’s disease (CD) and ulcerative colitis (UC). There has not yet been data published regarding efficacy of prolonged induction in CD or the efficacy of re-escalation to induction dosing in patients with either CD or UC. The aim of this study was to evaluate the real-world efficacy and safety of prolonged and/or re-escalation upadacitinib therapy in patients with inflammatory bowel disease (IBD) and prior inadequate response to standard upadacitinib treatment.

Methods

This was a retrospective, dual-center study of the efficacy of prolonged induction or re-escalation of upadacitinib in patients with IBD with prior inadequate response to standard upadacitinib treatment.

Results

Fifty-five patients met eligibility criteria. Thirty-nine (70.9%) persisted on upadacitinib therapy while 16 (29.1%) met the primary endpoint for upadacitinib failure. Of those that had comparative objective data, 62.5% had improvement in endoscopic activity, 100% had normalization of an elevated CRP, and 83.3% experienced a decrease in FCP by >50%. There were no new safety signals.

Conclusion

Over two-thirds of patients met the primary endpoint of persistence on therapy without requiring surgery, steroids, or additional biologic/small molecule inhibitor during follow-up. In a subset of patients who had adequate baseline and follow up objective data, the majority of patients had improvement in mucosal healing, decrease by 50% in FCP, and normalization of CRP. This study shows promising results that prolonged upadacitinib induction or dose re-escalation may improve clinical outcomes in a medically refractory patient population.

Schlagwörter

Stichwörter der Autor:innen

dose adjustmentinflammatory bowel diseasesmall moleculesupadacitinib

Autor:innen und Institutionen

  • Department of Medicine, Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY, United States.
  • Department of Medicine, Division of Gastroenterology and Hepatology, New York University Langone Health, New York, NY, United States.
  • Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD, United States.
  • Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, United States.
  • Division of Gastroenterology, MedStar Washington Hospital Center, Washington, DC, United States.
  • Mercy Medical Center, The Center for Inflammatory Bowel and Colorectal Diseases, Baltimore, MD, United States.

ORCID-Profile: Vasantham Chaudhary

Zitieren

APA

Axenfeld, E., Chaudhary, V., Clinton, J. W., Frohlinger, M., George, L., Cross, R. K., & Axelrad, J. E. (2026). Treatment outcomes of prolonged induction or re-escalation dosing of upadacitinib in patients with inflammatory bowel disease. Crohn’s & Colitis 360, 8(2). https://doi.org/10.1093/crocol/otag021

Vancouver

Axenfeld E, Chaudhary V, Clinton JW, Frohlinger M, George L, Cross RK, et al. Treatment outcomes of prolonged induction or re-escalation dosing of upadacitinib in patients with inflammatory bowel disease. Crohn’s & Colitis 360. 2026;8(2). doi:10.1093/crocol/otag021

BibTeX
@article{Axenfeld2026,
  author = {Axenfeld, Ellen and Chaudhary, Vasantham and Clinton, Joseph W and Frohlinger, Michael and George, Lauren and Cross, Raymond K and Axelrad, Jordan E},
  title = {Treatment outcomes of prolonged induction or re-escalation dosing of upadacitinib in patients with inflammatory bowel disease},
  journal = {Crohn’s & Colitis 360},
  year = {2026},
  volume = {8},
  number = {2},
  doi = {10.1093/crocol/otag021}
}
Kostenlos starten →